Beyond Cancer: Exploring CAR-T Therapy for Hemophilia and Transplant Rejection
Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape for hematologic malignancies, offering targeted, durable responses where conventional therapies often fall short. But what if this cellular precision could be redirected beyond cancer—to chronic, non-oncological diseases like hemophilia or transplant rejection?   Recent advances suggest that...
0 Comments 0 Shares 220 Views 0 Reviews
Sponsored
Sponsored
Sponsored
google-site-verification: google037b30823fc02426.html